Botanix Pharmaceuticals Ltd
BOT
Company Profile
Business description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
Contact
41 - 47 Colin Street
Suite 3
West PerthWA6005
AUST: +61 865552945
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,982.10 | 19.30 | -0.21% |
| CAC 40 | 7,850.43 | 106.02 | 1.37% |
| DAX 40 | 24,240.82 | 198.92 | 0.83% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,061.49 | 37.68 | 0.42% |
| HKSE | 25,668.02 | 129.95 | 0.51% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,890.49 | 719.17 | 1.75% |
| NZX 50 Index | 12,814.59 | 20.53 | 0.16% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,713.30 | 23.90 | -0.27% |
| SSE Composite Index | 3,599.44 | 17.14 | 0.48% |